StockIQ.techGilead Sciences Inc. (GILD) Stock Analysis
Free AI-powered analysis and research for Gilead Sciences Inc. stock
Sector: Healthcare
GILD snapshot
Data as of 4 Nov 2026 close. Updated daily.
Gilead Sciences Inc. scores 46/100 on StockIQ's model, which reads as mixed signals overall. The price is above its 200-day average and at 98% of its 52-week range, up 41.9% over the past year. Latest reported figures show a profit margin of -12.5%, return on equity of -22.4% and revenue growth of +6.8%.
What is driving the score
- Strong Uptrend: +12
- MACD Bullish: +8
- Unprofitable (-12.5%): -15
- High Debt (2.04 D/E): -10
- Weak Liquidity (1.32 Current Ratio): -5
- Negative ROE (-22.4%): -10
- High P/B (16.35): -5
- Strong Long-term Uptrend: +8
- Strong Momentum (+41.9% over 1 year): +8
- Near 52-Week High (98%): +5
Automated, general information only – not financial advice. Scores can be wrong. How the score works
Full GILD report
Gilead Sciences Inc. (GILD) is listed in the Healthcare sector. The snapshot on this page updates daily; run a full report for the complete breakdown.
Analyze GILD Now →📰 Latest Update
Gilead Sciences Stock: Analyst Estimates & Ratings
Tue, November 3, 2026 at 2:41 PM UTC 2 min read
The headline "Gilead Sciences Stock: Analyst Estimates & Ratings" suggests that analysts have provided updated estimates and ratings for Gilead Sciences' stock. This information is crucial for investors as it can influence market perceptions and investment decisions, reflecting analysts' views on the company's future performance and potential risks. Keeping track of these estimates helps investors gauge the stock's valuation and overall market sentiment.